Biotech Startups

BiOWiSH develops microbial-based biotechnology solutions for agriculture, aquaculture, and environmental management to improve soil health, crop yields, and sustainable food production. The company serves farmers and agricultural institutions globally with scientifically validated biological products.

2 investors

BioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

2 investors

Bioyond develops intelligent laboratory automation platforms and robotic systems for experimental research environments, including vision systems and scheduling software.

2 investors

Bitrobius develops gene therapy technologies, specifically the Gentrafix platform, leveraging microbial molecular biology and genetic engineering. The company serves therapeutic applications in areas including neurodegeneration and drug discovery.

2 investors

Blackbird Laboratories is a nonprofit life sciences incubator that translates university research breakthroughs into venture-ready biotech companies focused on developing new medicines and enabling technologies.

2 investors

Blazar develops software and methods that help biomedical and translational R&D teams structure workflows so that results, model outputs, and supporting evidence remain interpretable, comparable, and traceable as data, instruments, and protocols change over time. Its work originates in AI applied to pathology, biomarkers, and translational modelling in oncology research, and its tools emphasize documented assumptions, structured review, and human supervision.

2 investors

Bluestem Biosciences uses an industrial fermentation process with an engineered yeast strain to convert American corn into 3-hydroxypropionic acid (3-HP) and other platform chemicals, offering a domestic alternative to petroleum-based production. Its business model retrofits existing U.S. bioethanol facilities to produce these chemicals at commercial scale, targeting American manufacturing and agricultural supply chains.</parameter> <parameter name="founders">[]

2 investors

Bluewater Bio develops water treatment and environmental engineering solutions, serving clients across construction, industrial, and infrastructure projects globally.

2 investors

BlueWhale Bio develops manufacturing technologies for cell-based therapies, focusing on cell activation and expansion in early-stage processing to improve efficiency and reduce costs. The company serves medical institutions and therapeutics developers working with cell therapy products.

2 investors

Insilico Medicine applies artificial intelligence to biomarker development and drug discovery. The company builds AI-driven tools to connect biomarker research with the process of discovering new drugs.

2 investors

BoneSupport develops synthetic bone graft substitutes that remodel to match patient bone and elute antibiotics to prevent infection during healing. The products serve orthopedic surgeons and patients undergoing bone void procedures.

2 investors

Bonito develops encoded library and live-cell selection technologies to discover delivery ligands, generating high signal-to-noise data on membrane-bound targets to train AI models for precision drug delivery. The company combines functional selections with AI to turn physical delivery experiments into programmable ligand discovery.

2 investors

Bontia Bio is a synthetic biology company that uses proprietary fermentation technology to create natural bioactive compounds for animal health and agriculture, with its first product targeting fleas and ticks in companion animals.

2 investors

Bonumose produces tagatose, a naturally occurring "rare sugar" made from plant starch (corn, wheat, cassava) using proprietary enzymes, offering a sugar substitute with a low glycemic index and reduced calories. It supplies food manufacturers and consumers with tagatose and other rare ingredients for food, supplements, animal feed, crop protection, and soil health.

2 investors

A company developing products designed to preserve and provide beneficial bacteria from breast milk to support infant gut microbiome development. The company offers a preservation device for stored breast milk and a microbiome supplement containing live bacteria and prebiotics.

2 investors

Neurogenesis-based drug discovery company targeting depression, mood disorders and CNS diseases.

2 investors

Brandon BioCatalyst funds biomedical development opportunities associated with its Member Institutes, offering investments ranging from AU$500,000 to AU$30 million across stages from proof-of-concept to late-stage technologies. It operates an investment process through an Investment Review Committee, with due diligence handled by Brandon Capital.

2 investors

BRC Therapeutics develops and manufactures botanically-derived pharmaceutical products, with expertise spanning drug development and manufacturing for pharmaceutical applications.

2 investors

Breaking develops engineered microorganisms and enzymes—notably a microbe variant called MICROBE X-32—that biologically degrade many types of plastic waste into organic matter. The company also aims to create new bioplastics, chemical recycling via depolymerization, and biofuels/biomaterials, addressing plastic pollution and remediation.

2 investors

Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery. Its pipeline includes BT-267, a brain-penetrant LRRK2 inhibitor, and BT-409, an NLRP3 inflammasome inhibitor.

2 investors

Bright Biotech produces recombinant proteins, including growth factors, by expressing them in plant chloroplasts. Its proteins are aimed at cell culture and regenerative medicine applications.

2 investors

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.

2 investors

Wireless urologic sensing system for lower urinary tract symptoms such as incontinence, prostate issues, and neurogenic bladder.

2 investors

Bright Angel Therapeutics is a pre-clinical stage biotechnology company developing small-molecule antifungal therapeutics aimed at drug-resistant and life-threatening invasive fungal infections. It designs fungal-selective inhibitors targeting fungal stress responses, using Schrödinger's computational drug discovery platform alongside its own proprietary technologies.

2 investors